New drug approvals in 2022: Year-end review - On Demand

Each year the FDA approves a number of new medications. Some of these medications have the potential to have significant clinical impact. It is therefore important for health care practitioners to familiarize themselves with these approvals and understand how these new medications may affect current practice. This presentation will review new drug approvals from 2022 and highlight selected medications with the potential for significant clinical impact. 

Target Audience

This activity is intended for pharmacists and pharmacy technicians. 

Learning Objectives

Pharmacists learning objectives

At the conclusion of this activity, pharmacists should be able to:

 

Pharmacy technician learning objectives

At the conclusion of this activity, pharmacy technicians should be able to:

  • Identify resources for learning about new drug approvals

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Course opens: 
03/17/2023
Course expires: 
03/16/2024

Faculty

Kyle Hoelting, PharmD, BCPS
Sr. Clinical Manager Drug Information
Vizient, Inc.

John Schoen, PharmD, BCPS
Sr. Clinical Manager Drug Information
Vizient, Inc.


Planning Committee

Jackie Stokes, BS
Manager, Pharmacy Program
Vizient, Inc.

Gretchen Brummel, PharmD, BCPS
Consulting Solutions Director
Vizient, Inc.

 

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

Disclosure of Financial Relationships:

Absence of Relevant Financial Relationships

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

Statement of content validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

Off-label/unapproved drug uses or products are mentioned within this activity. 

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Designation Statement(s):

PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.

Universal Activity Number: JA0006103-0000-23-029-H01-P

Universal Activity Number: JA0006103-0000-23-029-H01-T

OTHER

Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Please login or register to take this course.